High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma
Launched by KENTUCKIANA CANCER INSTITUTE · Jan 26, 2006
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
This is a phase I/II study of high dose irinotecan in patients with recurrent unresectable malignant glioma on steroids/anti-epileptics. The purpose is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • recurrent, unresectable primary CNS neoplasm per MRI
- • ECOG status of 2 or less
- • no prior therapy with camptothecans
- • on an enzyme-inducing antiepileptic
About Kentuckiana Cancer Institute
Kentuckiana Cancer Institute is a leading clinical research organization dedicated to advancing cancer treatment through innovative trials and comprehensive patient care. With a focus on improving therapeutic options and outcomes, the institute collaborates with healthcare professionals and researchers to explore cutting-edge therapies and enhance understanding of various malignancies. Committed to patient safety and ethical standards, Kentuckiana Cancer Institute strives to contribute to the global fight against cancer while providing personalized support to individuals navigating their treatment journeys.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Louisville, Kentucky, United States
Patients applied
Trial Officials
Renato V. LaRocca, MD
Principal Investigator
Director
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials